Does Adjuvant Chemotherapy Dose Modification Have an Impact On the Outcome of Patients diagnosed with Advanced Stage Ovarian Cancer? An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: To determine the relationship between chemotherapy dose modification (dose adjustment or treatment delay), overall survival (OS) and progression-free survival (PFS) for women with advancedstage epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PPC) who receive carboplatin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Gynecol Oncol
Autores principales: Olawaiye, Alexander B., Java, James J., Krivak, Thomas C., Friedlander, Michael, Mutch, David G., Glaser, Gretchen, Geller, Melissa, O’Malley, David M., Wenham, Robert M., Lee, Roger B., Bodurka, Diane C., Herzog, Thomas J., Bookman, Michael A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151871/
https://ncbi.nlm.nih.gov/pubmed/30135020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.07.021
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares